Two Sigma Investments LP lowered its position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 65.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 180,465 shares of the company's stock after selling 339,957 shares during the period. Two Sigma Investments LP owned about 0.52% of RAPT Therapeutics worth $285,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Picton Mahoney Asset Management grew its position in RAPT Therapeutics by 994.4% during the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company's stock worth $26,000 after acquiring an additional 14,697 shares during the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of RAPT Therapeutics in the 4th quarter valued at about $63,000. Sei Investments Co. bought a new stake in shares of RAPT Therapeutics in the 4th quarter valued at about $64,000. Shay Capital LLC bought a new stake in shares of RAPT Therapeutics in the 4th quarter valued at about $81,000. Finally, SG Americas Securities LLC grew its position in shares of RAPT Therapeutics by 401.9% in the 4th quarter. SG Americas Securities LLC now owns 53,244 shares of the company's stock valued at $84,000 after buying an additional 42,636 shares during the last quarter. Institutional investors own 99.09% of the company's stock.
RAPT Therapeutics Stock Performance
Shares of NASDAQ:RAPT traded down $0.05 during midday trading on Friday, reaching $1.04. The company's stock had a trading volume of 617,864 shares, compared to its average volume of 1,284,716. The firm has a market capitalization of $137.58 million, a price-to-earnings ratio of -0.38 and a beta of -0.11. The firm has a 50 day moving average price of $0.92 and a two-hundred day moving average price of $1.12. RAPT Therapeutics, Inc. has a fifty-two week low of $0.71 and a fifty-two week high of $3.83.
RAPT Therapeutics shares are scheduled to reverse split before the market opens on Tuesday, June 17th. The 1-8 reverse split was announced on Friday, June 13th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, June 16th.
RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.23. As a group, research analysts anticipate that RAPT Therapeutics, Inc. will post -2.14 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of research firms have commented on RAPT. Wall Street Zen upgraded RAPT Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. HC Wainwright upgraded RAPT Therapeutics to a "strong-buy" rating and set a $6.00 price target on the stock in a research report on Thursday, May 22nd. Finally, UBS Group reduced their price target on RAPT Therapeutics from $2.00 to $1.00 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. One analyst has rated the stock with a sell rating, four have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, RAPT Therapeutics currently has an average rating of "Hold" and a consensus target price of $3.00.
Get Our Latest Research Report on RAPT
RAPT Therapeutics Profile
(
Free Report)
RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Read More
Before you consider RAPT Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RAPT Therapeutics wasn't on the list.
While RAPT Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
